Ankerstim lead

OCCIPITAL NERVE STIMULATION A PROMISING TREATMENT FOR INTRACTABLE CHRONIC CLUSTER
HEADACHE PATIENTS

Latest clinical evidence
READ THE RCT SUMMARY

NEW clinical evidence for ONS treatment

Further clinical evidence of intractable Chronic Cluster Headache (iCCH) patients receiving Occipital Nerve Stimulation (ONS) therapy has been released, confirming that ONS is a promising treatment that may reduce attacks frequency and intensity on these suffering patients1.

45%

had ≥ 50% reduction in CH Frequency1

55%

had ≥ 30% reduction in CH Frequency1

91%

would recommend ONS to other patients1

Expand All

ANKERSTIM™: THE ONLY LEAD SPECIFICALLY DESIGNED TO REDUCE ONS COMMON COMPLICATIONS*

The AnkerStimTM lead is designed to resist migration and improve comfort.

ANKERSTIM: AN INNOVATIVE LEAD DESIGNED TO REDUCE COMMON COMPLICATIONS
  • Lead tip features a dual-prong tine for lead fixation in the subcutaneous layer. Two additional single-prong tines provide extra fixation between the two proximal electrodes. These tines are designed to resist migration and avoid the use of anchors in the occipital area that were a source of discomfort at the implant site.
  • Flexible spring-coil electrodes adjust to the shape of the skull and are designed to improve comfort at the device site and lower the risk of skin erosion.
  • 14G curved introducer needle adjusts to the curvature of the skull to help facilitate lead implant.
  • 60 cm lead length allows for two strain relief loops along the lead trajectory intended to further resist lead dislodgement.

HOW ONS WORKS

WHAT DO THE EXPERTS THINK?

DOWNLOAD BROCHURES AND CLINICAL EVIDENCE

pdf Icon RCT Extract (.pdf)

| 145KB

Lastest clinical evidence
pdf HCP Brochure English (.pdf)

183KB

HCP Brochure English
pdf Patient Brochure English (.pdf)

161KB

Patient Brochure English

CONTACT US

For more information on Occipital Nerve Therapy, please fill out this form and a Medtronic representative will be in touch.

*Indicates Required Field

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative or consult the Medtronic website at www.medtronic.com
*

'For Implantable Pain Stimulation devices in Western Europe (status: June 2021) ‘

1

Wilbrink LA, de Coo IF, Doesborg PGG, Mulleners WM, Teernstra OPM, Bartels EC, Burger K, Wille F, van Dongen RTM, Kurt E, Spincemaille GH, Haan J, van Zwet EW, Huygen FJPM, Ferrari MD, for the ICON study group.  Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial. Lancet Neurol 2021; 20: 515–25.